CN106511689B - Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction - Google Patents
Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction Download PDFInfo
- Publication number
- CN106511689B CN106511689B CN201710051061.4A CN201710051061A CN106511689B CN 106511689 B CN106511689 B CN 106511689B CN 201710051061 A CN201710051061 A CN 201710051061A CN 106511689 B CN106511689 B CN 106511689B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 102
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 239000008280 blood Substances 0.000 title claims abstract description 38
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 210000003734 kidney Anatomy 0.000 title claims abstract description 25
- 230000007812 deficiency Effects 0.000 title claims abstract description 17
- 208000026351 Fallopian Tube disease Diseases 0.000 title abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 241000258920 Chilopoda Species 0.000 claims abstract description 17
- 235000021419 vinegar Nutrition 0.000 claims abstract description 17
- 239000000052 vinegar Substances 0.000 claims abstract description 17
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 16
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 16
- 241000283966 Pholidota <mammal> Species 0.000 claims abstract description 12
- 241000218176 Corydalis Species 0.000 claims abstract description 11
- 244000178320 Vaccaria pyramidata Species 0.000 claims abstract description 9
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 8
- 210000003038 endothelium Anatomy 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 239000009636 Huang Qi Substances 0.000 claims abstract description 7
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 241000123589 Dipsacus Species 0.000 claims description 7
- 241000208682 Liquidambar Species 0.000 claims description 7
- 235000006552 Liquidambar styraciflua Nutrition 0.000 claims description 7
- 244000148137 Patrinia villosa Species 0.000 claims description 7
- 235000019109 Patrinia villosa Nutrition 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 241000110637 Cuscuta chinensis Species 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000213006 Angelica dahurica Species 0.000 claims 1
- 240000001398 Typha domingensis Species 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 31
- 230000017531 blood circulation Effects 0.000 abstract description 19
- 230000001737 promoting effect Effects 0.000 abstract description 16
- 208000000509 infertility Diseases 0.000 abstract description 9
- 230000036512 infertility Effects 0.000 abstract description 9
- 231100000535 infertility Toxicity 0.000 abstract description 9
- 241000382455 Angelica sinensis Species 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 238000005728 strengthening Methods 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 230000000295 complement effect Effects 0.000 abstract description 2
- 210000003101 oviduct Anatomy 0.000 description 35
- 238000000034 method Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 6
- 208000030843 hydrosalpinx Diseases 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 244000132619 red sage Species 0.000 description 6
- 206010065789 Fallopian tube obstruction Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 240000000260 Typha latifolia Species 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 240000007371 Cuscuta campestris Species 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 244000236521 Bupleurum rotundifolium Species 0.000 description 3
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 description 3
- 244000150195 Cyperus longus Species 0.000 description 3
- 235000018109 Cyperus longus Nutrition 0.000 description 3
- 241000576429 Forsythia suspensa Species 0.000 description 3
- 241000931143 Gleditsia sinensis Species 0.000 description 3
- 229920000715 Mucilage Polymers 0.000 description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 3
- 208000007893 Salpingitis Diseases 0.000 description 3
- 244000058416 Scirpus paludosus Species 0.000 description 3
- 235000005010 Scirpus paludosus Nutrition 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229960003742 phenol Drugs 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 241000762515 Hydrosalpinx Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000030120 acrosome reaction Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 229960003666 liquefied phenol Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000008010 sperm capacitation Effects 0.000 description 1
- 230000009303 sperm storage Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere, which comprises the following raw materials: 25-35 parts of salvia miltiorrhiza, 10-14 parts of red paeony root, 2-4 parts of prepared pangolin scales, 10-14 parts of spina gleditsiae, 10-14 parts of fructus forsythiae, 16-20 parts of herba patriniae, 0.5-1.5 parts of centipede, 10-14 parts of cowherb seed, 10-14 parts of fructus liquidambaris, 10-14 parts of pollen typhae, 12-18 parts of semen cuscutae, 16-20 parts of radix dipsaci from Sichuan of China, 10-14 parts of radix bupleuri, 10-14 parts of rhizoma cyperi with vinegar, 16-20 parts of rhizoma corydalis with vinegar, 25-35 parts of radix astragali preparata, 10-14 parts of radix paeoniae alba, 10-14 parts of angelica sinensis, 10-14 parts of radix aucklandiae, 10-14 parts of endothelium corneum gigeriae. The traditional Chinese medicine composition provided by the invention has the advantages that the selected medicinal materials are appropriate in compatibility, the formula is refined, the functions complement each other, the purposes of promoting blood circulation and removing blood stasis, dredging channels and collaterals, strengthening body resistance and eliminating evil, and promoting blood circulation and tonifying kidney are achieved, and the medicines are used in a matching way, so that the traditional Chinese medicine composition has a targeted curative effect on infertility caused by female tubal obstruction, effusion and the like; the medicines are prepared in an adjuvant mode on the medicine property, so that the toxic and side effects are few, and the medicine is safe to take.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere.
Background
Infertility is a common gynecological disease, and the important cause of infertility is fallopian tube obstruction caused by salpingitis. Infertility in women of childbearing age is reported to account for 30% to 50% of infertility due to fallopian tube factors. The oviduct is one of the major components of the female reproductive system and has the physiological functions of transporting sperm, eggs and fertilized eggs and providing the sites for sperm storage, capacitation, acrosome reaction and fertilization. The fallopian tube has a fine structure and is easy to damage. The main cause of the disease is inflammation, which causes the fallopian tube to adhere to other adjacent tissues, thereby causing damage and deformation of the fallopian tube or reducing the mobility of the fallopian tube. Therefore, obstruction of any part of the fallopian tube may cause dysfunction of the fallopian tube resulting in infertility.
At present, most of Western medicine treatment for fallopian tube obstruction adopts operation treatment, and has the advantages of accurate positioning and definite curative effect; but the western medicine treatment has the defects of high price, easy relapse of the oviduct adhesion after the treatment and the like. The traditional Chinese medicine considers that the disease belongs to the blood stasis disease, the causes are seven-emotion damage, qi stagnation and blood stasis, exogenous invasion, cold coagulation and blood stasis, pathogenic heat and blood coagulation, damp heat and blood stasis, kidney deficiency and blood stasis and the like, the pathogenesis is related to the blood stasis, the blood stasis blocks the uterus, the qi and blood circulation is not smooth, the sperm and egg circulation is blocked, and the two sperms can not be combined to cause infertility. However, in the specific practice of traditional Chinese medicine treatment of tubal nowhere, the view point of dialectical treatment is not uniform, and some herbs that can strengthen blood circulation and remove blood stasis and dredge collaterals are treated from liver, and meanwhile, the dispersion of emotion is emphasized; some have the principles of activating blood circulation to dissipate blood stasis, warming channel to dispel cold, and relieving swelling and pain as a prescription; some of the medicines take the principles of clearing heat and promoting diuresis, and promoting blood circulation and removing obstruction in channels as a formula; the components are prepared according to different treatment ideas, so that the treatment effects on tubal nowhere are greatly different; in addition, the selection of the raw material medicines and the allocation of compatibility in the formula lack pertinence, and most of the medicines with the effects of tonifying qi, promoting blood circulation, removing blood stasis, dredging collaterals and the like are simply combined, so that the curative effect of most of the traditional Chinese medicines for treating tubal obstruction is still unsatisfactory, and even some medicines have certain side effects on the body of a patient.
Disclosure of Invention
Aiming at the prior art, the invention aims to provide a traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides a traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere, which comprises the following raw materials:
25-35 parts of salvia miltiorrhiza, 10-14 parts of red paeony root, 2-4 parts of prepared pangolin scales, 10-14 parts of spina gleditsiae, 10-14 parts of fructus forsythiae, 16-20 parts of herba patriniae, 0.5-1.5 parts of centipede, 10-14 parts of cowherb seed, 10-14 parts of fructus liquidambaris, 10-14 parts of pollen typhae, 12-18 parts of semen cuscutae, 16-20 parts of radix dipsaci from Sichuan of China, 10-14 parts of radix bupleuri, 10-14 parts of rhizoma cyperi with vinegar, 16-20 parts of rhizoma corydalis with vinegar, 25-35 parts of radix astragali preparata, 10-14 parts of radix paeoniae alba, 10-14 parts of angelica sinensis, 10-14 parts of radix aucklandiae, 10-14 parts of endothelium corneum gigeriae.
The invention discloses a traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere, which preferably comprises the following components:
30 parts of salvia miltiorrhiza, 12 parts of red paeony root, 3 parts of prepared pangolin scales, 12 parts of spina gleditsiae, 12 parts of fructus forsythiae, 18 parts of patrinia, 1 part of centipede, 12 parts of cowherb seed, 12 parts of beautiful sweetgum fruit, 12 parts of cattail pollen, 15 parts of Chinese dodder seed, 18 parts of dipsacus root, 12 parts of radix bupleuri, 12 parts of rhizoma cyperi with vinegar, 18 parts of rhizoma corydalis with vinegar, 30 parts of radix astragali preparata, 12 parts of white paeony root, 12 parts of Chinese angelica, 12 parts of costustoot, 12 parts of endothelium corneum gigeriae galli and 6 parts.
The compatibility mechanism of the traditional Chinese medicine composition is as follows: the red sage root, the red peony root and the stir-baked squama manitis are used as monarch drugs to promote blood circulation and remove blood stasis, dredge channels and collaterals and dredge chong and ren qi and blood, and the red peony root can clear heat and cool blood and prevent long-term stasis and heat transfer. Herba Patriniae, fructus forsythiae and spina Gleditsiae have effects of clearing away heat and dampness, removing toxic substance, relieving swelling, and removing residual toxic substances in blood; the dodder seed and the himalayan teasel root are used for tonifying kidney qi, the prepared astragalus root is used for tonifying qi, the Chinese angelica is used for replenishing blood and promoting blood circulation, and the effects of strengthening body resistance and eliminating evil, and promoting blood circulation and tonifying kidney are taken as ministerial drugs. Centipede, cowherb seed, beautiful sweetgum fruit and raw cattail pollen are used for dredging the channels and collaterals, promoting blood circulation and enhancing the power of promoting blood circulation and removing blood stasis; radix bupleuri, rhizoma cyperi, radix paeoniae alba, rhizoma corydalis with vinegar, liver soothing and qi regulating, liver softening and pain relieving, elecampane and endothelium corneum gigeriae galli, qi regulating and stomach harmonizing are all adjuvant drugs; prepared licorice root, radix Glycyrrhizae Praeparata, is used to regulate the effects of the drugs in the recipe.
The invention aims at dialectical treatment of blood stasis and kidney deficiency type tubal nowhere, combines a plurality of traditional Chinese medicines, plays roles of promoting blood circulation to remove blood stasis, dredging channels and collaterals, strengthening body resistance to eliminate pathogenic factors, and promoting blood circulation to tonify kidney together, has obvious synergistic effect, and fully plays a compatible relationship of mutual reinforcement and mutual assistance.
The selected medicinal materials in the formula are compatible with each other, the formula is refined, the medicinal materials supplement each other in function, and the aims of promoting blood circulation to remove blood stasis, dredging channels and collaterals, strengthening body resistance to eliminate pathogenic factors, and promoting blood circulation to tonify kidney are fulfilled, and the medicines are used in a matching way, so that the medicine has a targeted curative effect on infertility caused by female oviduct obstruction, hydrops and the like; the medicines are prepared in an adjuvant mode on the medicine property, so that the toxic and side effects are few, and the medicine is safe to take.
In the traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere, all raw material components are organic whole, and all raw material components are absent. In the research and development process, the inventor finds that the overall action effect of the traditional Chinese medicine composition is obviously reduced by reducing any one raw material component in the composition or replacing the raw material components of the traditional Chinese medicine composition by the raw material medicines with similar medicine properties; other raw material components are added on the basis of the traditional Chinese medicine composition, so that the overall effect of the traditional Chinese medicine composition is not obviously improved, and even the overall effect of the traditional Chinese medicine composition is reduced.
The Chinese medicinal composition for treating blood stasis and kidney deficiency type salpingemphraxis can be prepared by decocting the raw materials in water to obtain decoction; it can also be prepared by other methods. In a specific embodiment of the invention, the preparation method of the traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere comprises the following steps:
(1) wrapping pollen Typhae with gauze, mixing with Saviae Miltiorrhizae radix, radix Paeoniae Rubra, spina Gleditsiae, fructus forsythiae, herba Patriniae, semen Vaccariae, fructus Lipuidambaris, semen Cuscutae, radix Dipsaci, bupleuri radix, rhizoma Cyperi, rhizoma corydalis, radix astragali Preparata, radix Paeoniae alba, radix Angelicae sinensis, radix aucklandiae, endothelium corneum Gigeriae Galli, and radix Glycyrrhizae Preparata, decocting with water twice, filtering (adding 8-10 times of water for decocting for 30-60 min for the first time, adding 6-8 times of water for decocting for 20-40 min for the second time), and mixing filtrates;
(2) slightly frying the centipedes to be crisp, grinding the centipedes to be fine, then adding the fine powder and the processed pangolin scales into the filtrate obtained in the step (1), and uniformly mixing the fine powder and the filtrate to obtain the centipede.
The traditional Chinese medicine components are complex, one medicinal material contains water-soluble components and oil-soluble or alcohol-soluble components, and some active components are easy to inactivate at high temperature, so that the effective components of the traditional Chinese medicine can be extracted and separated to the maximum extent by selecting a proper extraction method and an appropriate extraction process, and the activity of the effective components is ensured, thereby ensuring the clinical effect of the product.
Experiments prove that by adopting the preparation method, the effective components in the traditional Chinese medicine composition can be extracted to the maximum extent and the activity of the effective components is ensured, so that the clinical effect of the product is ensured.
The application of the traditional Chinese medicine composition in preparing a medicinal preparation for treating blood stasis and kidney deficiency type tubal nowhere is also within the protection scope of the invention.
The invention provides a pharmaceutical preparation for treating blood stasis and kidney deficiency type tubal nowhere, which is prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials.
The above medicinal preparation can be made into various dosage forms, such as pill, capsule, tablet, powder, granule or oral liquid.
The pharmaceutically acceptable auxiliary materials are conventional auxiliary materials in medicinal preparations, such as: disintegrants, lubricants, binders, and the like; preferably one or more of glycerol, butanediol, trehalose, betaine, starch, and sodium carboxymethylcellulose.
The traditional Chinese medicine composition or the pharmaceutical preparation has the following effects: activating collaterals, promoting blood circulation, removing blood stasis, relieving pain, and tonifying kidney. It is indicated for syndrome of blood stasis and kidney deficiency. The symptoms of lower abdomen pain or stabbing pain, lumbosacral ache, aggravation of lumbocrural pain during menstruation, much leucorrhea, white or yellow color, dark menstrual color with lumps, mental fatigue and hypodynamia, and dark and gloomy complexion; dark tongue with ecchymosis and petechia, thin and white coating, and deep and unsmooth pulse. Is suitable for patients with fallopian tube obstruction, hydrosalpinx, pelvic cavity adhesion or hysteroscopy operation, and the like.
The invention has the beneficial effects that:
the traditional Chinese medicine composition provided by the invention has the advantages that the selected medicinal materials are appropriate in compatibility, the formula is refined, the functions complement each other, the purposes of promoting blood circulation and removing blood stasis, dredging channels and collaterals, strengthening body resistance and eliminating evil, and promoting blood circulation and tonifying kidney are achieved, and the medicines are used in a matching way, so that the traditional Chinese medicine composition has a targeted curative effect on infertility caused by female tubal obstruction, effusion and the like; the medicines are prepared in an adjuvant mode on the medicine property, so that the toxic and side effects are few, and the medicine is safe to take.
Detailed Description
The present invention is further illustrated by the following specific examples, which should be construed as merely illustrative, and not limitative of the remainder of the disclosure.
Example 1:
the formula is as follows: 30g of salvia miltiorrhiza, 12g of red paeony root, 3g of prepared pangolin scales, 12g of spina gleditsiae, 12g of fructus forsythiae, 18 g of dahurian patrinia herb, 1g of centipede, 12g of cowherb seed, 12g of beautiful sweetgum fruit, 12g of cattail pollen, 15 g of south dodder seed, 18 g of himalayan teasel root, 12g of Chinese thorowax root, 12g of nutgrass galingale rhizome with vinegar, 18 g of corydalis tuber with vinegar, 30g of roasted astragalus root, 12g of white paeony root, 12g of Chinese angelica, 12g of costustoot, 12.
The preparation method comprises the following steps:
(1) wrapping pollen Typhae with gauze, mixing with Saviae Miltiorrhizae radix, radix Paeoniae Rubra, spina Gleditsiae, fructus forsythiae, herba Patriniae, semen Vaccariae, fructus Lipuidambaris, semen Cuscutae, radix Dipsaci, bupleuri radix, rhizoma Cyperi, rhizoma corydalis, radix astragali Preparata, radix Paeoniae alba, radix Angelicae sinensis, radix aucklandiae, endothelium corneum Gigeriae Galli, and radix Glycyrrhizae Preparata, decocting with water twice, filtering (adding 10 times of water for decocting for 40 min for the first time and 8 times of water for decocting for 30 min for the second time), and mixing filtrates;
(2) slightly frying the centipedes to be crisp, grinding the centipedes to be fine, then adding the fine powder and the processed pangolin scales into the filtrate obtained in the step (1), and uniformly mixing the fine powder and the filtrate to obtain the centipede.
The preparation is orally taken twice a day in the morning and at night, and 15 days are a treatment course.
Example 2:
the formula is as follows: 25g of salvia miltiorrhiza, 14 g of red peony root, 2g of prepared pangolin scales, 14 g of Chinese honeylocust spine, 10 g of weeping forsythia, 20 g of dahurian patrinia herb, 0.5 g of centipede, 14 g of cowherb seed, 10 g of beautiful sweetgum fruit, 14 g of cattail pollen, 12g of south dodder seed, 20 g of himalayan teasel root, 10 g of Chinese thorowax root, 14 g of nutgrass galingale rhizome with vinegar, 16 g of corydalis tuber with vinegar, 35 g of prepared astragalus root, 10 g of white paeony root, 14 g of Chinese angelica, 10 g of costustoot, 14 g.
The preparation method is the same as example 1.
Example 3:
the formula is as follows: 35 g of salvia miltiorrhiza, 10 g of red peony root, 4g of prepared pangolin scales, 10 g of Chinese honeylocust spine, 14 g of weeping forsythia, 16 g of dahurian patrinia herb, 1.5 g of centipede, 10 g of cowherb seed, 14 g of beautiful sweetgum fruit, 10 g of cattail pollen, 18 g of south dodder seed, 16 g of himalayan teasel root, 14 g of Chinese thorowax root, 10 g of nutgrass galingale rhizome with vinegar, 20 g of corydalis tuber with vinegar, 25g of prepared astragalus root, 14 g of white paeony root, 10 g of Chinese angelica, 14 g of costustoot, 10 g.
The preparation method is the same as example 1.
Example 4:
the filtrate obtained after the decoction in example 1 is prepared into capsules by a conventional method, and the specification is 0.25 g/capsule.
Example 5:
the decocted filtrate of example 1 is prepared into pills by a conventional method.
Example 6:
the filtrate obtained in the decoction of example 1 is prepared into granules by a conventional method.
Comparative example 1:
the inventor conducts investigation of compatibility and research of drug effects on multiple raw material medicines with similar drug properties in the research and development process, and finds that even if the drug properties of a certain raw material medicine are similar, the difference of the drug effects is obvious after the raw material medicine is compatible with other different raw material medicines.
For example: radix bupleuri, angelica, red paeony root, fried pangolin, cortex moutan, cowherb seed, spina gleditsiae, dandelion, beautiful sweetgum fruit, dahurian patrinia herb, bitter orange, himalayan teasel root, medicinal cyathula root and liquorice.
An oviduct inflammatory occlusion rat model is established by a conventional method, the treatment effect of the traditional Chinese medicine composition of the embodiment 1 and the comparative example 1 on the oviduct obstruction is considered, and animal experiments show that the treatment effect of the traditional Chinese medicine composition of the embodiment 1 on the oviduct obstruction is obviously better than that of the comparative example 1. The composition conforms to the compatibility of the traditional Chinese medicines, has a synergistic effect among the components, and is not simple replacement or combination of the raw material medicines with similar medicinal properties.
Comparative example 2:
the dosage of each raw material medicine in the traditional Chinese medicine composition is marked, even if the medicine composition of the prescription is the same, if the dosage of the medicine is different, the efficacy of the medicine is divided into different magnitudes, and the compatibility relationship is changed by monarch, minister, assistant and guide, so that the efficacy is different. The inventor researches the content of each raw material in the traditional Chinese medicine composition and the drug effect in the research and development process, and finds that the difference of the drug effect is obvious when the ratio of the unsuitable raw materials is different, especially when the monarch drug and the ministerial drug are different in the occupied parts. For example: the preparation method is that the dosage of the salvia miltiorrhiza in the example 1 is adjusted to 40 g, the dosage of the red paeony root is adjusted to 5g, the dosage of the stir-fried pangolin scales is adjusted to 5g, the dosage of the dahurian patrinia herb is adjusted to 25g, the dosage of the weeping forsythia capsule is adjusted to 5g, the dosage of the Chinese honeylocust spine is adjusted to 18 g, and the dosages of other raw materials are the same as the example 1 and are prepared according to the method of the example 1.
An oviduct inflammatory occlusion rat model is established by a conventional method, the treatment effect of the traditional Chinese medicine composition of the embodiment 1 and the comparative example 2 on the oviduct obstruction is considered, and animal experiments show that the treatment effect of the traditional Chinese medicine composition of the embodiment 1 on the oviduct obstruction is obviously better than that of the comparative example 2. The dosage of each raw material medicine in the composition is not obtained by conventional adjustment, and in the traditional Chinese medicine formula, the dosage and the proportion of each raw material medicine are determined according to various consideration factors such as the characteristics of the raw materials, monarch, minister, assistant and guide compatibility and the like, so that the composition plays an important role in the overall efficacy of the traditional Chinese medicine composition.
Animal experiments:
1. the influence of the traditional Chinese medicine composition on the patency of fallopian tube of a fallopian tube inflammatory occlusion model rat
(1) The test method comprises the following steps:
1) animal molding:
taking Wistar rats (female, 4-6 weeks old, 180-200 g in weight and clean grade) as test animals, performing intraperitoneal injection by aid of a uterine rat method by aid of pentobarbital sodium (25mg/kg), after anesthesia for 10-15 minutes, cutting off abdominal hair, sterilizing by aid of iodine tincture and alcohol, opening the abdominal cavity, respectively injecting 20% phenol mucilage into two fallopian tubes at positions, close to the fallopian tubes, of the uterus, and suturing wounds;
the preparation method of the 20% phenol mucilage comprises the following steps: liquefied phenol 5ml, Arabic gum 1g, glycerin 4ml, distilled water to 25ml, paste, injection 0.04 ml.
2) Test grouping and dosing:
wistar rats were randomly divided into 10 normal control groups (sham) and 50 building groups. The model group is randomly divided into 5 groups after the operation, each group comprises 10 models, namely a model control group, a positive medicine group and low, medium and high dose groups of the traditional Chinese medicine composition. The intragastric administration is started on the 2 nd day after the operation, the intragastric volume is 10ml/kg, and the continuous 35 days are carried out.
Wherein, the normal control group and the model control group are infused with distilled water; the low, medium and high dosage components of the traditional Chinese medicine composition of the invention are respectively infused in stomach, and the traditional Chinese medicine composition (prepared in example 1) is respectively: the low-dose group is 6g crude drugs/kg.d, the medium-dose group is 12g crude drugs/kg.d, and the high-dose group is 24g crude drugs/kg.d, which are respectively equal to 4 times, 8 times and 16 times of the clinical common dose; the positive drug group is the enema granules for treating the pelvic inflammation, and the dose is 3 g/(kg.d) (which is equivalent to 20 times of the clinical daily dose) for administration. After 35 days of intragastric administration, the rats were sacrificed and the fallopian tubes were examined for patency by injecting a diluted methylene solution from the uterus into the fallopian tubes.
(3) And (3) test results:
the test results are shown in Table 1.
Table 1:
as can be seen from Table 1, the number of the fallopian tube unobstructed cases of the model control group rats is obviously reduced compared with that of the normal control group, and the significant difference (P is less than 0.01) is generated, which indicates that the fallopian tube inflammatory obstruction can be caused by injecting 0.04ml of 20% phenol mucilage into the fallopian tubes at two sides. The number of the fallopian tube unobstructed cases of the rats in the positive drug group and the low, medium and high dose groups of the traditional Chinese medicine composition is increased compared with that of the rats in the model control group, which shows that the positive drug (pelvic inflammation eliminating granule) and the traditional Chinese medicine composition have an effect on the fallopian tube unobstructed of the rats in the salpingitis obstructive model; compared with the positive drug group, the traditional Chinese medicine composition has more obvious dredging effect on the oviduct of a model rat by the medium-dose group and the high-dose group.
And (3) safety test:
(1) acute toxicity test:
the traditional Chinese medicine composition is administrated by intragastric administration at the maximum concentration and the maximum volume, the continuous administration is carried out for 3 times within 24 hours, each time is 4 hours, and the total accumulated medicine amount reaches 30 g/kg. Within 7 days after administration, the mice had normal activity, feed and excretion, good growth and bright hair color, and their average body weight increased with the duration of the test. And (3) killing the test mouse at the 8 th day, and carrying out systematic necropsy, organ coefficient and histology examination, wherein the result is abnormal, which shows that the traditional Chinese medicine composition has no acute toxic reaction.
(2) Long-term toxicity test:
the traditional Chinese medicine composition is divided into three dose groups of 5.0g (crude drug)/kg/day, 10.0g (crude drug)/kg/day and 15.0g (crude drug)/kg/day, and after 2 months of continuous gavage administration, test mice are sacrificed to measure various indexes. Observation and measurement items include, for example, physical signs and behavioral activities, secretions, stool characteristics; conventional and biochemical indices of blood; the contents of the system autopsy, organ coefficients, and histological examination.
The results show that: the continuous oral administration of the composition to mice at different doses had no effect on the food intake and weight gain of the mice. No obvious toxic effect on the functions of the liver and the kidney is found; the safety and the non-toxicity of the traditional Chinese medicine composition are proved.
And (3) clinical trials:
1. study object
120 patients with fallopian tube obstruction who come to hospital for treatment in 5 months 2014 and 2012 were selected, and the selected patients were randomly divided into a treatment group and a control group, wherein each group comprises 60 patients. The age, disease course and the like of the treatment group and the control group have no significant significance (p is more than 0.05), and the treatment group and the control group have comparability.
2. The diagnosis method comprises the following steps: patency of the fallopian tubes was evaluated clinically by laparoscopy.
3. The treatment method comprises the following steps:
the treatment group orally takes the decoction prepared in the embodiment 1 of the invention twice a day, once in the morning and at night, and 15 days are a treatment course.
The pelvic inflammation treating granule is orally taken in a control group according to instructions, and 15 days are a treatment course.
After 3 treatment courses, the patency of the oviduct was known by oviduct angiography and statistically analyzed.
4. The curative effect standard is as follows:
(1) and (3) curing: after the treatment is finished, the affected fallopian tube can be observed to realize unobstructed again through salpingography, and the patient is pregnant through 1 year follow-up.
(2) The method has the following advantages: the patency of the affected fallopian tube is obviously improved through the observation of salpingography after the treatment is finished.
(3) And (4) invalidation: the smooth degree of the fallopian tube is not obviously improved or aggravated.
5. As a result:
the results are shown in Table 1.
Table 1: therapeutic results
Warp X2The total effective rate of the treatment group on the oviduct obstruction is obviously improved (P) compared with the control group by inspection<0.05), no adverse reaction during the treatment process. The traditional Chinese medicine composition has good clinical treatment effect on fallopian tube obstruction, and is safe and free of toxic and side effects.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be able to cover the technical solutions and the inventive concepts of the present invention within the technical scope of the present invention.
Claims (6)
1. A traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal nowhere is characterized by comprising the following raw materials: 30 parts of salvia miltiorrhiza, 12 parts of red paeony root, 3 parts of prepared pangolin scales, 12 parts of spina gleditsiae, 12 parts of fructus forsythiae, 18 parts of patrinia, 1 part of centipede, 12 parts of cowherb seed, 12 parts of beautiful sweetgum fruit, 12 parts of cattail pollen, 15 parts of Chinese dodder seed, 18 parts of dipsacus root, 12 parts of radix bupleuri, 12 parts of rhizoma cyperi with vinegar, 18 parts of rhizoma corydalis with vinegar, 30 parts of radix astragali preparata, 12 parts of white paeony root, 12 parts of Chinese angelica, 12 parts of costustoot, 12 parts of endothelium corneum gigeriae galli and 6 parts.
2. The preparation method of the traditional Chinese medicine composition of claim 1, which is characterized by comprising the following steps:
(1) wrapping pollen Typhae with gauze, mixing with Saviae Miltiorrhizae radix, radix Paeoniae Rubra, spina Gleditsiae, fructus forsythiae, herba Patriniae, semen Vaccariae, fructus Lipuidambaris, semen Cuscutae, radix Dipsaci, bupleuri radix, rhizoma Cyperi processed with vinegar, rhizoma corydalis processed with vinegar, radix astragali Preparata, radix Paeoniae alba, radix Angelicae sinensis, radix aucklandiae, endothelium corneum Gigeriae Galli, and radix Glycyrrhizae Preparata, decocting with water twice, filtering, and mixing filtrates;
(2) slightly frying the centipedes to be crisp, grinding the centipedes to be fine, then adding the fine powder and the processed pangolin scales into the filtrate obtained in the step (1), and uniformly mixing the fine powder and the filtrate to obtain the centipede.
3. The preparation method according to claim 2, wherein the water decoction is carried out by the specific steps of: adding 8-10 times of water for the first time, and decocting for 30-60 minutes; adding 6-8 times of water for the second time, and decocting for 20-40 minutes.
4. A pharmaceutical preparation for treating blood stasis and kidney deficiency type tubal nowhere is prepared from the traditional Chinese medicine composition of claim 1 or 2 and pharmaceutically acceptable auxiliary materials.
5. The pharmaceutical formulation of claim 4, wherein the pharmaceutically acceptable excipient is a disintegrant, a lubricant, or a binder.
6. The pharmaceutical preparation according to claim 4, wherein the pharmaceutical preparation is in the form of a pill, capsule, tablet, powder, granule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710051061.4A CN106511689B (en) | 2017-01-23 | 2017-01-23 | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710051061.4A CN106511689B (en) | 2017-01-23 | 2017-01-23 | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106511689A CN106511689A (en) | 2017-03-22 |
| CN106511689B true CN106511689B (en) | 2020-01-14 |
Family
ID=58337053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710051061.4A Active CN106511689B (en) | 2017-01-23 | 2017-01-23 | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511689B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567871A (en) * | 2018-01-25 | 2018-09-25 | 徐光亮 | It is a kind of to treat infertile medicine pill |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949664A (en) * | 2012-11-13 | 2013-03-06 | 刘晓燕 | Traditional Chinese medicinal composite for treating fallopian-tube obstructive infertility |
-
2017
- 2017-01-23 CN CN201710051061.4A patent/CN106511689B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949664A (en) * | 2012-11-13 | 2013-03-06 | 刘晓燕 | Traditional Chinese medicinal composite for treating fallopian-tube obstructive infertility |
Non-Patent Citations (1)
| Title |
|---|
| 刘瑞芬辨治输卵管性不孕经验;武志娟 等;《辽宁中医杂志》;20130618;第40卷(第6期);第1089页左栏第3段至右栏第3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106511689A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461921B (en) | Medicinal composition for treating gynecopathy | |
| CN100427063C (en) | An wind-expelling ointment and method for preparing same | |
| CN108785422B (en) | Traditional Chinese medicine composition for treating acute mastitis and preparation method thereof | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| CN103638366B (en) | A kind of Chinese medicine for vaginal discharge diseases of women and preparation method thereof | |
| CN101564486A (en) | Medicament for preventing and treating ruminant post-natal diseases and preparation method thereof | |
| CN103494962B (en) | Traditional Chinese medicine composition capable of clearing heat and detoxifying | |
| CN103157014B (en) | Miao medicine for treating tumors | |
| CN105055841A (en) | Medicine for treating chronic pharyngitis and preparing method thereof | |
| CN102526342B (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN106511689B (en) | Traditional Chinese medicine composition for treating blood stasis and kidney deficiency type tubal obstruction | |
| CN101804189B (en) | Drug for treating primary dysmenorrhea | |
| CN103908611A (en) | Traditional Chinese medicine preparation for treating colon cancer and preparation method of traditional Chinese medicine preparation | |
| CN105194584A (en) | Medicine for treating dysmenorrhea | |
| CN102379963B (en) | Skin wound treating ointment and preparation method thereof | |
| CN104435484A (en) | Seven connected traditional Chinese medicine packets for treating colorectal cancer | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN106729327B (en) | Traditional Chinese medicine composition for treating qi-blood deficiency and kidney deficiency type irregular menstruation | |
| CN101966278B (en) | Traditional Chinese medicine for treating urinary tract infection and preparation method thereof | |
| CN104587389A (en) | Traditional Chinese medicine composition for treating neck shoulder pain and lumbocrural pain | |
| CN104274746B (en) | Pharmaceutical composition for treating pharyngitis | |
| CN111759997B (en) | Traditional Chinese medicine decoction for treating hyperplasia of mammary glands | |
| CN115814040B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation thereof | |
| CN105031552A (en) | Traditional Chinese medicine composition for treating gynecological tumors | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |